Importantly, we currently are performing a clinical trial (ClinicalTrials.gov NCT04146298) to evaluate the safety and efficacy of our identified HLA-A*11:01–restricted KRAS G12V8–16–specific TCR in a TCR-gene therapy trial for patients with advanced pancreatic cancer. The gene discussed is HLA-A; the disease is familial pancreatic carcinoma.